Cytodyn Inc (CYDY)

[Saltz]

If Bruce Patterson is correct and I believe he is, Leronlimab is going to disrupt the BP food chain and much more along the way.

The manipulation and fabrication of misinformation is but one example of a desperate and unethical attempt to inhibit the reallocation of Billions of $’s.

Success from a new player is always met with skepticism and resistance whether it be moving from the minor leagues to the majors in baseball or obscurity to disrupting SOC in the biotech world.

CYDY has the goods and the science is gaining traction. The scramble to shed doubt and mount an offensive by the parties that will be displaced is to be expected.

Gilead and Fauchi pulled quite a move on April 16th that exemplifies just that. They changed the metrics and primary end point to get into scoring position first. They reached base on an error not a legitimate base hit.

“Government clinical trial investigators changed the primary metric for measuring the success of Gilead’s experimental drug remdesivir.”

“Instead of counting how many people taking the drug were kept alive on ventilators or died, among other measures, the National Institute of Allergy and Infectious Diseases said it would judge the drug primarily on a different outcome: how long it took surviving patients to recover.”

“The switch — which specialists said is unusual in major clinical trials but not unheard of — was publicly disclosed on the government’s clinicaltrials.gov website on April 16 but did not receive much attention at the time.”

“I think that they thought they weren’t going to win, and they wanted to change it to something they could win on,'' said Steven Nissen, a Cleveland Clinic cardiologist and expert clinical investigator who has led numerous drug trials. “I prefer the original outcome. It’s harder. It’s a more meaningful endpoint.”

“Getting out of the hospital early is useful,'' he said, “but it’s not a game-changer.''

Fauchi and Gilead has set the SOC bar very low. Is it any wonder why Gilead’s CEO, O’Day made the decision to give the drug away at no cost. It has very little value and he knows it.

Leronlimab’s current 75 patient blinded placebo trial results will certainly shine a very bright light on Remdesivir’s shortcomings.

The full story:

https://www.washingtonpost.com/business/2020/05/01/government-researchers-changed-metric-measure-coronavirus-drug-remdesivir-during-clinical-trial/